+

PE20080053A1 - Composiciones oftalmicas de alcaftadina - Google Patents

Composiciones oftalmicas de alcaftadina

Info

Publication number
PE20080053A1
PE20080053A1 PE2007000398A PE2007000398A PE20080053A1 PE 20080053 A1 PE20080053 A1 PE 20080053A1 PE 2007000398 A PE2007000398 A PE 2007000398A PE 2007000398 A PE2007000398 A PE 2007000398A PE 20080053 A1 PE20080053 A1 PE 20080053A1
Authority
PE
Peru
Prior art keywords
alcaftadine
ophthalmic compositions
eye
ophthalmic
imidaze
Prior art date
Application number
PE2007000398A
Other languages
English (en)
Inventor
Jagdish Parasrampuria
Avner Ingerman
Frans Janssens
Anton Megens
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Publication of PE20080053A1 publication Critical patent/PE20080053A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION OFTALMICA QUE COMPRENDE DE 0,005% A 10% POR PESO DE ALCAFTADINA (6,11-DIHIDRO-11-(1-METIL-4-PIPERIDINILIDENO)-5H-IMIDAZO[2,1-b][3]BENZAZEPINA-3-CARBOXALDEHIDO) Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. DICHA FORMULACION SE PRESENTA BAJO LA FORMA DE SOLUCION O SUSPENSION OFTALMICA Y ES UTIL EN EL TRATAMIENTO DE ENROJECIMIENTO OCULAR, PICAZON OCULAR, HINCHAZON DE PARPADOS, QUEMOSIS, ENTRE OTRAS
PE2007000398A 2006-03-31 2007-04-02 Composiciones oftalmicas de alcaftadina PE20080053A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19

Publications (1)

Publication Number Publication Date
PE20080053A1 true PE20080053A1 (es) 2008-03-10

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000398A PE20080053A1 (es) 2006-03-31 2007-04-02 Composiciones oftalmicas de alcaftadina

Country Status (30)

Country Link
US (8) US8664215B2 (es)
EP (2) EP2004196B1 (es)
JP (3) JP5292277B2 (es)
KR (1) KR101321731B1 (es)
CN (1) CN102895234A (es)
AR (1) AR060278A1 (es)
AU (1) AU2007234957B2 (es)
BR (1) BRPI0710085B8 (es)
CA (1) CA2648115C (es)
CL (1) CL2007000916A1 (es)
CR (1) CR10414A (es)
DK (2) DK2004196T3 (es)
EA (1) EA016221B1 (es)
EC (1) ECSP088786A (es)
ES (2) ES2752823T3 (es)
HK (1) HK1131331A1 (es)
IL (1) IL194473A (es)
JO (1) JO3358B1 (es)
MX (1) MX2008012657A (es)
MY (1) MY153669A (es)
NI (1) NI200800261A (es)
NO (1) NO341147B1 (es)
NZ (1) NZ571690A (es)
PE (1) PE20080053A1 (es)
PL (2) PL2004196T3 (es)
SG (1) SG170044A1 (es)
TW (2) TWI450721B (es)
UY (1) UY30254A1 (es)
WO (1) WO2007117971A2 (es)
ZA (1) ZA200809327B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101321731B1 (ko) 2006-03-31 2013-10-30 비스타콘 파머수티컬즈, 엘엘씨 눈 알레르기 치료
EP2015733A2 (en) 2006-04-26 2009-01-21 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
CN101977595A (zh) * 2007-11-08 2011-02-16 阿西克斯医疗公司 用于治疗以及预防眼睑肿胀的组合物
EP3943069B1 (en) 2009-03-17 2024-11-27 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US9409913B2 (en) * 2012-11-21 2016-08-09 Enaltec Labs Private Limited Polymorphic forms of alcaftadine
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
EP3496662A4 (en) 2016-08-12 2019-10-30 Silk Technologies Ltd. PROTEIN DERIVED FROM SILK FOR THE TREATMENT OF INFLAMMATION
JP7191022B2 (ja) * 2017-07-28 2022-12-16 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
KR20200035047A (ko) * 2017-08-03 2020-04-01 산텐 세이야꾸 가부시키가이샤 클로르헥시딘을 함유하는 의약 조성물
ES2878107T3 (es) * 2018-01-18 2021-11-18 Faes Farma Sa Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
EP4164614A1 (en) 2020-06-15 2023-04-19 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
KR20230150840A (ko) 2021-02-24 2023-10-31 오큘라 테라퓨틱스, 인코포레이티드 소관내 데포 삽입 디바이스
CA3213156A1 (en) * 2021-04-01 2022-10-06 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
JPWO2024010044A1 (es) * 2022-07-06 2024-01-11
EP4534081A1 (en) * 2022-07-06 2025-04-09 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
CN116473937A (zh) * 2022-11-29 2023-07-25 嘉兴学院 一种具有抗恶性黑素瘤作用的仿生纳米颗粒及制备方法和应用
TW202448475A (zh) * 2023-03-31 2024-12-16 日商樂敦製藥股份有限公司 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) * 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
CA2093797C (en) 1990-10-10 1998-09-22 Richard J. Friary Substituted imidazobenzazepines and imidazopyridoazepines
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
WO2007109523A2 (en) * 2006-03-17 2007-09-27 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
KR101321731B1 (ko) 2006-03-31 2013-10-30 비스타콘 파머수티컬즈, 엘엘씨 눈 알레르기 치료

Also Published As

Publication number Publication date
US8664215B2 (en) 2014-03-04
NO341147B1 (no) 2017-09-04
ES2594655T3 (es) 2016-12-21
JP2013144703A (ja) 2013-07-25
AR060278A1 (es) 2008-06-04
IL194473A0 (en) 2009-08-03
EA200870396A1 (ru) 2009-04-28
NZ571690A (en) 2011-09-30
TWI450721B (zh) 2014-09-01
JP2015131820A (ja) 2015-07-23
EP2004196B1 (en) 2016-06-29
UY30254A1 (es) 2007-08-31
EA016221B1 (ru) 2012-03-30
CN102895234A (zh) 2013-01-30
BRPI0710085B8 (pt) 2021-05-25
US20170065605A1 (en) 2017-03-09
AU2007234957B2 (en) 2012-12-13
SG170044A1 (en) 2011-04-29
EP2004196A2 (en) 2008-12-24
KR101321731B1 (ko) 2013-10-30
KR20080110881A (ko) 2008-12-19
ES2752823T3 (es) 2020-04-06
JP2009533333A (ja) 2009-09-17
BRPI0710085B1 (pt) 2019-12-17
DK2004196T3 (en) 2016-09-05
TWI578990B (zh) 2017-04-21
US20120094978A1 (en) 2012-04-19
CA2648115A1 (en) 2007-10-18
TW200815016A (en) 2008-04-01
CA2648115C (en) 2015-03-24
CR10414A (es) 2009-02-23
EP3150209A1 (en) 2017-04-05
NI200800261A (es) 2012-10-30
AU2007234957A1 (en) 2007-10-18
US10617695B2 (en) 2020-04-14
CL2007000916A1 (es) 2008-01-25
US20240058355A1 (en) 2024-02-22
TW201446249A (zh) 2014-12-16
US20230181594A1 (en) 2023-06-15
BRPI0710085A2 (pt) 2011-08-23
US20140107102A1 (en) 2014-04-17
NO20084593L (no) 2008-10-29
PL3150209T3 (pl) 2020-03-31
MX2008012657A (es) 2009-02-19
JP5292277B2 (ja) 2013-09-18
JO3358B1 (ar) 2019-03-13
WO2007117971A3 (en) 2007-12-27
US20080051385A1 (en) 2008-02-28
IL194473A (en) 2016-04-21
JP6039716B2 (ja) 2016-12-07
PL2004196T3 (pl) 2017-01-31
HK1131331A1 (en) 2010-01-22
US20210030762A1 (en) 2021-02-04
EP3150209B1 (en) 2019-07-24
ZA200809327B (en) 2009-12-30
US20250108059A1 (en) 2025-04-03
WO2007117971A2 (en) 2007-10-18
MY153669A (en) 2015-03-13
ECSP088786A (es) 2009-01-30
DK3150209T3 (da) 2019-10-28

Similar Documents

Publication Publication Date Title
PE20080053A1 (es) Composiciones oftalmicas de alcaftadina
HRP20050845A2 (en) Prostaglandin analogs as ep4 receptor antagonists
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
BRPI0512569A (pt) métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
CL2009000400A1 (es) Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
MA31953B1 (fr) Nouveaux derives du thiophene.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
CL2007003821A1 (es) Compuestos derivados de isoquinolina o isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades asociadas con la rho-quinasa y/o la fosforilacion mediada por la rho-quinasa de la cadena ligera de miosina, tales como hipertension, retinopatia, glaucoma, alzheimer, sida entre otras.
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
UY31430A1 (es) Derivados de piridina y pirazina -83
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
RU2012103538A (ru) Композиции и способы ингибирования пути jak
EA200900582A1 (ru) Фармацевтические композиции для профилактики и лечения глазных патологий
ES2182973T3 (es) Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
BRPI0705978A2 (pt) composiÇÕes de lubrificante pessoal e kits para proporcionar lubrificaÇço pessoal
MX2011008680A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
ECSP066808A (es) Solución oftálmica que comprende carboximetilcelulosa de sodio e hidroxipropilmetilcelulosa
GT200900173A (es) Dispersión sólida de un antagonista de neuroquinina
MX2010000130A (es) Derivados de 3-espiropirimidintriona-quinolina y su uso como agentes antibacterianos.
TW200722420A (en) Propane-1,3-dion derivative or salt thereof

Legal Events

Date Code Title Description
FG Grant, registration
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载